Ornella Zollo

Ornella Zollo has a diverse work experience in the field of scientific research. Ornella is currently working as a Principal Scientist at SwanBio Therapeutics since September 2022. Prior to this, they served as a Senior Scientist at PTC Therapeutics, Inc. from June 2021 to December 2021.

Ornella worked for Bristol-Myers Squibb as a Scientist from October 2016 to May 2021. Before that, they were a Research Scientist at ONCOVEDA Cancer Research Center from October 2015 to September 2016. Ornella also held a similar role as a Research Scientist at Temple University from November 2014 to October 2015.

Ornella's early experience includes a position as a Research Technician II at The Children's Hospital of Philadelphia from September 2010 to June 2014. Ornella then furthered their career as a Postdoctoral Fellow at both UCSF and Fox Chase Cancer Center. At UCSF, they spearheaded a project focused on understanding the role of the initiation factor of translation, eIF4E, in cancer initiation downstream the PI3K signal transduction pathway. Their contributions included generating a tissue-specific inducible transgenic mouse expressing a phosphorylation-defective 4E-BP1 mutant, which resulted in increased survival and decreased lymphomagenesis in AKT transgenic mice. Ornella worked at UCSF from June 2007 to December 2007.

Prior to their postdoctoral position at UCSF, they held the role of Postdoctoral Fellow American-Italian Cancer Foundation at Fox Chase Cancer Center from June 2005 to June 2007. In this role, they conducted similar research on the contribution of eIF4E to cancer initiation and generated a tissue-specific inducible transgenic mouse expressing a phosphorylation-defective 4E-BP1 mutant.

Ornella Zollo began their research career as a Research Scientist at the University of Perugia, where they worked from March 2000 to June 2005.

Overall, Ornella Zollo has a strong background in scientific research, with experiences in both academic and industry settings. Their expertise lies in the investigation of the molecular mechanisms underlying cancer initiation and the development of novel therapeutic approaches.

Ornella Zollo completed their Master of Science (MS) in Molecular and Cellular Biology at the Università degli Studi di Perugia from 1989 to 1994. Ornella then pursued a Doctor of Philosophy (PhD) in Immunology at the Sapienza Università di Roma, which they completed from 1994 to 2000.